Stem Cell Clinic

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on October 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Originally posted here:
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

MONMOUTH JUNCTION, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the completion of patient enrollment for its planned open-label safety study evaluating ONS-5010/LYTENAVA™ (NORSE THREE). Patient enrollment for the study was completed in less than one month, significantly ahead of the planned four-month enrollment schedule.

See the original post here:
Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Abcam plc: Annual Report, Impact Report and Notice of AGM

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 September 2020 of its final results for the year ended 30 June 2020, the Abcam plc Annual Report and Accounts 2020 (the “Annual Report”) have been published today and are available on the Abcam plc website at www.abcamplc.com.

See original here:
Abcam plc: Annual Report, Impact Report and Notice of AGM

Ocuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330

Live Webinar Featuring 3 KOLs Focused on Front and Back of the Eye Conditions and Opportunities for New Treatments on Monday, November 9, at 10:00am ET Live Webinar Featuring 3 KOLs Focused on Front and Back of the Eye Conditions and Opportunities for New Treatments on Monday, November 9, at 10:00am ET

Read more here:
Ocuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330

Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Link:
Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update

BioNTech to Report Third Quarter 2020 Financial Results and Operational Update on November 10, 2020

Originally posted here:
BioNTech to Report Third Quarter 2020 Financial Results and Operational Update on November 10, 2020

CRISPR-Focused Excision BioTherapeutics Announces Business Advisory Board and Addition of Interim Chief Business Officer

First members include industry veterans with backgrounds at Merck, Pfizer, Novartis, and more First members include industry veterans with backgrounds at Merck, Pfizer, Novartis, and more

Visit link:
CRISPR-Focused Excision BioTherapeutics Announces Business Advisory Board and Addition of Interim Chief Business Officer

Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients

Nes Ziona, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health authorized the initiation of a proposed Company-sponsored Phase IIb clinical trial evaluating Allocetra™,  in sepsis patients.

Read more from the original source:
Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients

Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET

HANOVER, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical need conditions, today announces it will host a conference call and live webcast on Nov. 12, 2020, at 5:30 p.m. Eastern time to discuss its third quarter 2020 results and provide an update on the Company’s clinical pipeline. The update will include a discussion of the Company’s three clinical-stage drugs (each of which addresses potential billion-dollar markets):

Continue reading here:
Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET

Tauriga Sciences Inc. Reports Continued Growth in its E-Commerce Business With a 25.8% Increase in Average Order Size

NEW YORK, NY, Nov. 03, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that during October 2020, the Company reported continued growth in its highest margin E-Commerce business segment. Additionally, there was a sharp increase (more than 25%) in the average order size – with respect to each individual On-Line E-Commerce transaction.  The Company’s E-Commerce business is its highest margin segment and there are a number of potential future catalysts that the Company believes can fuel future growth.

Read more here:
Tauriga Sciences Inc. Reports Continued Growth in its E-Commerce Business With a 25.8% Increase in Average Order Size